News: Allos Therapeutics Inc (ALTH.O)
5.88USD
17 Dec 2009
$-0.13 (-2.16%)
$6.01
$6.00
$6.00
$5.86
731,691
2,945,943
$9.30
$5.22
Mon, Dec 7 2009
UPDATE 3-Celgene to buy Gloucester in cancer drug deal
* Gloucester lymphoma drug won U.S. approval last month
CORRECTED - UPDATE 2-Celgene to buy Gloucester in cancer drug deal
(Deletes reference to Celgene shares rising in 5th paragraph)
UPDATE 1-Allos says Idis to supply its cancer drug outside US
* Says Idis to manage named patient program outside U.S.
UPDATE 2-Allos Therapeutics' cancer drug gets FDA nod, shares up
* Shares rise 6 pct (Adds analyst comment, details from conference call, updates share movement)
HEADLINE STOCKS-Some U.S. stocks to watch on Sept. 25
NEW YORK, Sept 25 (Reuters) - Some U.S. stocks to watch on Friday:
Allos Theraputics up after FDA OK's Folotyn
NEW YORK (Reuters) - Allos Therapeutics Inc shares jumped 8.5 percent to $8.84 in premarket on Friday after the U.S. Food and Drug Administration approved its Folotyn treatment for relapsed or refractory peripheral t-cell lymphoma.
BEFORE THE BELL-Allos Theraputics up after FDA OK's Folotyn
NEW YORK, Sept 25 (Reuters) - Allos Therapeutics Inc shares jumped 8.5 percent to $8.84 in premarket on Friday after the U.S. Food and Drug Administration approved its Folotyn treatment for relapsed or refractory peripheral t-cell lymphoma. [ID:nWNAB3342]
HEADLINE STOCKS-Some U.S. stocks on the move on Sept 3
(Updates to afternoon trading, adds Amedisys, Jackson Hewitt, Zumiez, Hovnanian, Diebold, Arena, Quanex, Anadarko)
HEADLINE STOCKS-Some U.S. stocks on the move on Sept 3
(Updates to after the open, adds Target, Gap, Macy's, JC Penney, Abercrombie, Family Dollar, Del Monte, Methode, Vical, Movado, Beckton Dickinson, Danaher, Teekay and Helicos)
HEADLINE STOCKS-Some U.S. stocks to watch on Sept 3
NEW YORK, Sept 3 (Reuters) - Some U.S. stocks to watch on Thursday:
Press Releases
- Allos Therapeutics` FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Allos Therapeutics` FOLOTYN Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
- Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN at 51st ASH Annual Meeting
- Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN (pralatrexate injection)
- Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
